Scotiabank raised the firm’s price target on Disc Medicine (IRON) to $70 from $62 and keeps an Outperform rating on the shares. The firm views the company’s end-of-phase 2 FDA meeting update as a ...
BMO Capital raised the firm’s price target on Disc Medicine (IRON) to $112 from $70 and keeps an Outperform rating on the shares. Following the “positive” regulatory update for bitopertin, the firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results